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Abstract
Background. Withdrawal of steroids should be
attempted after organ transplantation because of
their adverse cardiovascular and metabolic effects.
However, immunological, haemodynamic and
symptomatic complications may occur due to the
suppression of endogenous corticoid hormone syn-
thesis under exogenous steroid intake. We have
examined the effect of chronic steroid medication on
adrenocortical function, and of steroid withdrawal,
in immunologically stable renal transplant patients.
Methods. Sixty-three patients under long-term predni-
sone therapy (mean±SD 36±47 months) were
assessed regarding basal fasting cortisol concentration
and adrenocortical stimulation by the low-dose Synac-
ten test both prior to and after stepwise prednisone
withdrawal. Renal graft function (determined as the
calculated glomerular ﬁltration rate according to the
Cockroft–Gault formula), mean arterial blood pres-
sure and clinical status were evaluated concomitantly.
Results. Basal fasting cortisol concentration was
clearly suppressed in 14% of patients under long-
term steroid medication, and adrenocortical stimula-
tion by the low-dose Synacten test was impaired in
31% after steroid withdrawal. About a third of all
patients were symptomatic with fatigue (60%), arthral-
gias (60%), muscular weakness (20%), loss of appetite
(20%), hypotension (15%) or headaches (5%). The
incidence of symptoms was much higher in patients
with low basal fasting cortisol concentration prior to
steroid withdrawal, and after >2 years of steroid
medication. Renal graft function, determined as glo-
merular ﬁltration rate, decreased only slightly overall
by 5%, and was more pronounced in symptomatic
vs asymptomatic patients (7 vs 2ml/min, respec-
tively), as was the fall in mean arterial pressure (10 vs
4.2mmHg, respectively).
Conclusions. Adrenal function is impaired in renal
transplant patients receiving long-term steroid medica-
tion as part of their immunosuppressive regimen. This
may lead to mainly symptomatic complications when
steroids are withdrawn. The slight decrease in glomeru-
lar ﬁltration rate probably can be ascribed mostly
to the effect of steroids on systemic renal haemo-
dynamics. It is recommended to consider cessation
of steroid medication within 48 months of therapy,
and after determination of basal cortisol to identify
patients with potential complications.
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Introduction
Corticosteroids have been the cornerstone of immuno-
suppressive therapy in transplant medicine for decades.
Even with the advent of newer, more speciﬁc and
increasingly potent immunosuppressants, such as calci-
neurin inhibitors, mycophenolate or sirolimus, steroids
have remained part of the initial immunosuppressive
regimen after kidney transplantation in most centres.
However, due to their untoward metabolic and
cardiovascular effects, it is recommended to withdraw
corticosteroids if the immunological situation of the
patient allows for it [1]. Unfortunately, both short- and
long-term glucocorticoid treatment in non-transplant
patients has been reported to cause transient adreno-
cortical dysfunction due to suppression of the hypotha-
lamo-adrenal axis by exogenous steroid administration
[2–4]. Thus, cessation of long-term steroid medication
may be difﬁcult, not only from an immunlogical point
of view with the risk of acute rejection episodes in
transplant patients, but also due to impairment of
adrenocortical function with symptomatic manifesta-
tions from steroid withdrawal (SW). In addition,
Correspondence and offprint requests to: Patrice M. Ambu¨hl, Renal
Division, University Hospital, Ra¨mistrasse 100, CH-8091 Zurich,
Switzerland. E-mail: patrice.ambuehl@dim.usz.ch
Nephrol Dial Transplant Vol. 19 No. 10  ERA–EDTA 2004; all rights reserved
cessation of exogenous steroid intake may impact on
the renal transplant independently of immunological
mechanisms. Animal studies by Baylis Brenner et al.
have shown corticosteroids to increase renal plasma
ﬂow and thus glomerular ﬁltration rate (GFR) [5].
Based on this knowledge, one would expect cessation of
long-term steroid administration to impair renal graft
function acutely. Similarly, a decrease in systemic blood
pressure has to be postulated because of the salt and
water retention attributed to steroid hormones.
However, no data are available from the literature on
adrenocortical function in renal transplant patients
under long-term steroid medication, and on the con-
sequences of steroid withdrawal with regard to adreno-
cortical response and its relationship to changes in renal
function, systemic blood pressure and the develop-
ment of symptomatic complications. Therefore, it was
the aim of this study to examine the effect of chronic
steroid therapy on adrenocortical function, and of the
withdrawal from long-term corticosteroid medication
on graft function, arterial blood pressure and the
potential development of symptomatic complications
from adrenal insufﬁciency in immunologically stable
renal transplant patients.
Materials and methods
A cohort of 63 solid organ transplant patients with SW
between October 2001 and June 2003 were included
prospectively in this single-centre study. Fifty-ﬁve kidney
transplant patients were on cyclosporin A (CyA)/mycopheno-
late mofetil (MMF)-based immunosuppression, while eight
patients with combined kidney and pancreas grafts were
treated with tacrolimus and MMF. Recent publications
have reported the feasibility of SW in the latter group of
patients [6]. Most of the patients were recipients of a ﬁrst
graft, with only three having undergone repetitive transplan-
tation. The baseline characteristics of all patients are listed
in Table 1.
All patients were on medication with 10mg of prednisone
(PDN) per day at baseline for at least 6 months. SW was
then carried out stepwise over 2 weeks by ﬁrst tapering the
PDN dose to 5mg before complete withdrawal (Figure 1).
Basal fasting cortisol (BFC) was assessed in all 63 patients
at baseline and 1 week after SW between 8 and 9 a.m. The
normal range of BFC as deﬁned for the employed assay is
171–536 nmol/l. Plasma cortisol was measured by ECLIA
(Roche Diagnostics, Mannheim, Germany), with a coefﬁ-
cient of variation of 2.9%. This assay does not interfere with
exogenously administered synthetic steroids or their metab-
olites, and, therefore, exclusively detects endogenous corti-
costeroid hormones. In a subgroup of 32 patients, adrenal
function was examined by low-dose Synacten (tetracosac-
tide, Novartis Pharma, Switzerland) stimulation (LDS;
intravenous bolus injection of 1mg tetracosactide) at baseline
and after SW. The commercially available 250 mg vials of
Synacten were diluted by the hospital pharmacy to 1 mg/ml
in chemically inert plastic tubes and stored at 4C until use
within 24 h. The LDS test is established and widely validated
with a high speciﬁcity and sensitivity both for detection of
primary hypoadrenalism and the assessment of adrenocor-
tical function in patients under exogenous steroid medication
[7–10]. In accordance with other authors, a plasma cortisol
concentration of >550 nmol/l after 30min of Synacten
injection had been deﬁned as being indicative for adequate
adrenal response [4].
Clinical evaluation and data collection were performed
at baseline, 1 week after steroid tapering to 5mg, and ﬁnally
1 week after completion of SW. Longer follow-up beyond
3 months after the ﬁnal predeﬁned time point was available
for most patients. Patients were interviewed and examined
with particular emphasis on typical symptoms of SW-like
fatigue, malaise, loss of appetite, headache as well as muscle
and joint pain. All patients were negative regarding these
symptoms and in a stable general condition prior to initiation
of steroid tapering. Furthermore, renal function was assessed
by serum creatinine (SCr) and calculated GFR according
to the Cockroft–Gault formula. Changes in systemic arterial
blood pressure throughout SW were determined in a sitting
position on the upper extremities. For the purpose of
comparison between groups, mean arterial pressure (MAP)
was used.
For data analysis, patients were divided into subgroups
according to BFC concentration prior to SW (group A, BFC
<171nmol/l; group B, BFC >170 nmol/l). The two groups
were then compared regarding renal function, MAP and
clinical symptoms. Similarly, results were analysed indepen-
dently of the presence or absence of symptoms related to SW.
Finally, the subgroup of patients subjected to the LDS test
was divided further and analysed according to their adreno-
cortical response upon stimulation after PDN therapy had
been stopped [group C, stimulated plasma cortisol (CST)
Table 1. Baseline characteristics of the study population
All patients (n¼ 63)
Cadaveric/living donor, n 47/16
Transplanted organ
Kidney (n) 55
Kidney and pancreas (n) 8
Age (years) 45.8 (12.2)
Male:female ratio 44:19
Number of Tx
1 59
2 3
3 1
Time after last transplantation (months) 27 (36)
Time on steroids (months) 36 (47)
Serum creatinine (mmol/l) 122.2 (23.8)
GFR (ml/min) 65.3 (14.6)
MAP (mmHg) 101.9 (12.6)
All results are means; SDs are given in parentheses.
GFR¼ glomerular ﬁltration rate; MAP¼mean arterial blood
pressure.
BASAL FASTING CORTISOL            X X
LOW-DOSE SYNACTEN TEST          X                                                                              X
CLINICAL EXAMINATION                  X X  X 
PREDNISONE DAILY DOSE          10 mg                           5 mg                                    0 mg
Week 0 1 2 3
Fig. 1. Schedule of steroid withdrawal.
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concentration <550 nmol/l; group D, plasma CST concentra-
tion >550 nmol/l].
All patients participating in the study have given written
informed consent. The study protocol was performed
according the guidelines of the institutional ethics committee.
All results are expressed as means and SD unless stated
otherwise. Differences between groups were analysed by
paired or unpaired Student’s t-test, as appropriate, with
a P-value <0.05 indicating statistical signiﬁcance.
Results
The effects of SW as analysed in all patients are
summarized in Table 2. The mean BFC concentration
before and after SW was within the normal range, but
slightly lower after SW compared with baseline by
20%. SCr increased from 122 mmol/l at baseline to
130 mmol/l 1 week after SW (P¼ 0.0001), correspond-
ing to a drop in GFR of 5% from 65 to 62ml/min.
MAP decreased signiﬁcantly after SW from 102 to
96mmHg (P¼ 0.0002). Whereas none of the patients
were reporting any particular symptoms prior to ini-
tiation of steroid tapering, 20 patients (32%) developed
one or more symptoms typically related to SW after
medication had been stopped completely. In their order
of frequency, the most commonly cited were fatigue
(60%), arthralgias (60%), muscular weakness (20%),
loss of appetite (20%), hypotension (15%) or head-
aches (5%). The occurrence of symptoms and/or
worsening of renal transplant function necessitated
the reinstitution of steroid medication in seven patients.
The reasons and outcomes are listed in Table 3. As
shown, another attempt to withdraw steroids later
on was successful in one of these seven patients, and
PDN dose could be reduced to 5mg/day in two other
patients.
A minority of nine patients (14%) had inadequately
low BFC levels prior to cessation of steroid therapy
(groupA), deﬁned as a BFC of<171 nmol/l.MeanBFC
Table 2. Characteristics of all transplant patients subjected to steroid withdrawal and randomization according to baseline basal fasting
cortisol
All patients Group A (BFC <171nmol/l) Group B (BFC >170 nmol/l)
n (%) 63 (100) 9 (14) 54 (86)
Age (years) 45.8 (12.2) 39.3 (7.9)* 46.9 (12.5)
Gender ratio, M:F 44:19 5:4 39:15
Time on steroids (months) 36 (47) 34.0 (45.3) 46.8 (59.9)
Baseline After SW Baseline After SW Baseline After SW
BFC (nmol/l) 459 (205) 376 (122)þ 71 (52)y 311 (96) 523 (137) 387 (124)
SCr (mmol/l) 122 (23.8) 130 (28.3)þ 116 (24.1) 125 (21.3) 123 (23.8) 131 (29.4)
GFR (ml/min) 65 (14.6) 62 (14.4) 68 (13.4) 63 (15.0) 65 (14.9) 62 (14.5)
MAP (mmHg) 102 (12.6) 96 (12.1)þ 100 (8.5) 97 (7.4) 102 (13.2) 96 (12.7)
Change in GFR (ml/min) 3.6 (7.3) 4.9 (8.0) 3.3 (7.3)
Change in MAP (mmHg) 6.1 (12.6) 3.1 (5.4) 6.6 (13.4)
Symptoms of SW n (%) 20 (32) 9 (100) 11 (20)
All results are means; SDs are given in parentheses.
BFC¼ basal fasting cortisol; SCr¼ serum creatinine; GFR¼ glomerular ﬁltration rate; MAP¼mean arterial blood pressure; SW¼ steroid
withdrawal.
*P¼ 0.04 vs group B; þP<0.001 vs baseline in all patients; yP<0.0001 vs baseline in group B.
Table 3. Reinstitution of steroid medication in seven of 63 patients after steroid withdrawal
Patient TOS
(months)
BFC
(nmol/l)
Reason for reinstitution Days
after
SW
Follow-up/outcome
G.R., 44-year-old male 8 516 Rise in serum creatinine
because of post-renal obstruction
30 Surgical intervention with normalization
of serum creatinine; PDN discontinued
B.P., 66-year-old male 63 344 Hypotension, loss of appetite, fatigue 16 Prompt recovery under continued
low-dose steroid medication (5mg/day)
R.A., 27-year-old male 8 482 Asymptomatic rise in serum creatinine 70 Creatinine normalized, steroids continued
(10mg/day)
M.E., 49-year-old female 100 451 Fatigue, rise in serum creatinine due to
pre-renal complication (acute diarrhoea)
9 Complete recovery; low-dose steroids
continued (5mg/day)
L.S., 45-year-old male 163 573 Fatigue, joint pain, loss of appetite,
rise in serum creatinine
29 Complete recovery, steroids continued
(10mg/day)
C.C., 58-year-old male 127 572 Joint pain 16 Recovered; steroids continued
(10mg/day)
S.I., 70-year-old female 15 695 Fatigue, joint pain, loss of appetite,
rise in serum creatinine
7 Recovered; steroids continued
(10mg/day)
TOS¼ time on steroids prior to withdrawal; BFC¼ basal fasting cortisol prior to steroid withdrawal; SW¼ steroid withdrawal.
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at baseline in group A was lower by 8-fold compared
with patients with normal BFC (group B). Patients of
group A were slightly younger, and low BFC concen-
tration was clearly associated with the occurrence of
clinical symptoms related to SW (with a prevalence
of 100% in group A, vs 20% in group B). However,
no signiﬁcant differences between groups were noticed
regarding renal function, blood pressure and time
on steroids. It is of note that the difference in mean
BFC concentration after SW was clearly less between
groups, indicating that in some of the patients
from group A cortisol production was about to be
restored.
Comparing symptomatic with asymptomatic patients
after SW, some important differences could be detected
(Table 4). As a reﬂection of the ﬁndings reported in
Table 2, BFC prior to SW was signiﬁcantly higher in
asymptomatic compared with symptomatic patients
by 2-fold. The individual correlation of BFC prior
to and after cessation of steroids in patients with and
without symptoms is shown in Figure 2. In addition to
low BFC, renal function was signiﬁcantly worse in
symptomatic vs asymptomatic patients, as revealed by
the differences in SCr and GFR. Also, blood pressure
was signiﬁcantly lower in symptomatic patients after
SW compared with patients without symptoms, with a
mean decrease in MAP of 10.0 and 4.2mmHg,
respectively. Finally, symptomatic patients had been
on steroids signiﬁcantly longer than patients without
symptoms from SW.
The subgroup of patients tested for adrenal response
by LDS (n¼ 32; Table 5) was comparable with the
entire cohort (Table 2) regarding the baseline char-
acteristics such as age, gender, duration of steroid
medication, BFC, GFR and MAP. Ten of these
patients (31%) presented with an impaired adrenal
response to LDS (group C), deﬁned as a plasma CST
concentration below 550 nmol/l at the start of SW.
Compared with the 22 patients (69%) with normal
adrenocortical response (group D), their CST concen-
tration 1 week after SW was 35% lower. Impaired
adrenal response after SW was associated with both
longer time on steroid medication (by 2-fold) and
higher incidence of symptoms related to SW (by
55%). In contrast, no signiﬁcant differences were
found with respect to patient age, changes in SCr,
GFR and MAP (Table 5).
Discussion
Due to its untoward metabolic effects on bone, carbo-
hydrate metabolism and the cardiovascular system,
it is desirable to withdraw corticosteroid medication
after kidney transplantation in immunologically stable
patients. Many studies have investigated the feasibility
of steroid-free immunosuppression regarding long-
term graft survival. However, to the best of our
knowledge, this is the ﬁrst study that reports on the
short-term effects of SWwith respect to haemodynamic
stability, graft function and clinical symptoms of SW
in renal transplant patients. The main ﬁndings of our
experiments are that (i) a substantial proportion of
patients on long-term corticosteroid treatment have
a suppressed adrenocortical function with inadequate
response of the adrenal glands upon stimulation;
(ii) nevertheless, SW can be performed safely in the
vast majority of chronically stable renal transplant
patients with regard to preservation of graft function;
and (iii) the limiting factor for successful SW is the
development of symptoms such as musculoskeletal
Table 4. Patients with symptomatic compared with patients with
asymptomatic steroid withdrawal
Symptomatic Asymptomatic
n¼ 63 (100%) 20 (32) 43 (68)
Age (years) 45.5 (11.3) 46.0 (12.5)
Gender ratio
M:F
13:7 31:12
Baseline After SW Baseline After SW
BFC (nmol/l) 287 (222) 326 (121)þ 539 (137)þ 400 (117)
CST (nmol/l)* 503 (198) 573 (109) 653 (125) 632 (126)
Increased
cortisol
(nmol/l)*
153 (150) 227 (55) 86 (89) 220 (122)
SCr (mmol/l) 123 (23.3) 140 (35.8)þ 122 (24.1) 126 (26.3)
GFR (ml/min) 64.5 (16.9) 57.5 (16.4) 65.7 (15.2) 63.8 (14.3)
MAP (mmHg) 102 (9.2) 92 (10.7) 101 (14.1) 98 (12.3)y
Change in
GFR
(ml/min)
7.0 (8.1) 2.0 (6.4)y
Change in
MAP
(mmHg)
10.0 (12.3) 4.2 (12.4)y
Time on
steroids
(months)
58 (53) 25 (40)z
All results are means; SDs are given in parentheses.
BFC¼basal fasting cortisol; CST¼ stimulated cortisol; SCr¼
serum creatinine; GFR¼ glomerular ﬁltration rate; MAP¼mean
arterial blood pressure; SW¼ steroid withdrawal.
*n¼ 32.
þP<0.001 vs baseline in symptomatic patients; yP<0.05 vs in
symptomatic patients after SW; zP¼ 0.004 vs in symptomatic
patients.
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2618 M. Miozzari and P. M. Ambu¨hl
pain, fatigue and hypotension, which can be predicted
by basal plasma cortisol concentration prior to cessa-
tion of corticosteroid therapy.
Among our cohort of chronically stable renal trans-
plant patients, who have been on corticosteroid treat-
ment for an average of 3 years, about a third had
an impaired adrenocortical function, with either low
BFC concentration (<171 nmol/l) in 14% or inade-
quate adrenocortical response upon stimulation with a
synthetic derivative of adrenocorticotrophic hormone
(ACTH; tetracosactide, Synacten) in 32% of subjects.
One may argue that steroid tapering in our study
was faster compared with current practice, and may
account for the ﬁndings reported above. Nevertheless,
the incidence of adrenal insufﬁciency in our cohort
is lower compared with results from studies in non-
transplant patients after both long-term and short-term
glucocorticoid therapy, which revealed an impaired
adrenocortical response in 63 [2] and 45% [4] of
patients, respectively. One may speculate on whether
transplant patients behave differently from patients
who receive steroid medication for other reasons,
i.e. inﬂammatory or autoimmune disease. One such
potential difference may be the concurrent therapy with
other immunosuppressive drugs in transplant patients
that can interfere with the action and/or the metab-
olism of corticosteroids, as described for CyA [11,12].
However, the average CyA dose used in our study
was not different between patients with and without
impaired adrenocortical response (data not shown).
Alternatively, the regulation of adrenal tissue, that
variably is transplanted with a renal graft, may be
regulated differently from that of ‘native’ kidneys.
With regard to the implications of the observed
impairment in adrenocortical function in renal trans-
plant patients under long-term steroid medication,
one has to differentiate direct effects on the graft
from other consequences. It is reassuring to notice
that SW had almost no impact on graft function in this
study, at least in short-term follow-up. Although the
mean GFR was reduced by 4ml/min immediately
after SW, corresponding to a decrease in renal trans-
plant function of <6%, only a few patients were
suspected to have a rejection episode. Consequently,
GFR stabilized in virtually all patients either sponta-
neously or after reintroduction of steroid medication
during several weeks of follow-up, and no patient
required anti-rejection therapy. Although many other
studies have demonstrated that SW is possible in a
majority of patients without relevant rejection episodes
(for a review see [13]), the particularly favourable
outcome in our patient cohort may be explained mainly
by two facts: all patients were under an immuno-
suppressive regimen based on CyA and MMF, and
were selected for SW only when they had a previously
stable graft function. The slight and transient decrease
in GFR that nevertheless occurred is in accordance
with the effect of corticosteroids on renal haemody-
namics and the regulation of intraglomerular pressure
[5]. As corticosteroids can increase intraglomerular
ﬁltration pressure and, thereby, GFR, it is conceivable
that SW may have the opposite effect. Thus, many
of the renal transplant patients undergoing cessation
of long-term steroid medication with consecutive
deterioration of renal graft function may not necessar-
ily experience a rejection episode, and, therefore,
reintroduction of steroid therapy may be unnecessary.
In the present study, there was a trend towards a more
pronounced drop in GFR in patients with low BFC
(Table 2), and in those with symptoms after SW. These
ﬁndings are in accordance with the aforementioned
hypothesis. However, no such correlation was found
Table 5. Characteristics of patients subjected to steroid withdrawal assessed by low-dose ACTH adrenal stimulation test (LDS), and
comparison of subgroups according to adrenal response upon LDS
All patients Group C (CST <550nmol/l) Group D (CST >549 nmol/l)
n (%) 32 (100) 10 (31) 22 (69)
Age (years) 48.6 (11.4) 43.9 (6.7) 49 (12.6)
Gender ratio M:F 24:8 9:1 15:7
Time on steroids (months) 49.1 (56.3) 91.8 (84.5)* 42.6 (54.1)
Baseline After SW Baseline After SW Baseline After SW
BFC (nmol/l) 483 (188) 383 (120) 399 (207) 261 (58)y 514 (176) 441 (94)
CST (nmol/l) 592 (165) 595 (135) 466 (164)z 432 (67)y 643 (139) 669 (82)
 cortisol CST–BFC (nmol/l) 111 (117) 223 (101) 60 (81) 171 (103) 129 (124) 227 (116)
 cortisol CST–BFC (%) 55 (98) 67 (37) 67 (124) 74 (47) 51 (89) 57 (36)
SC (mmol/l) 130 (25.2) 138 (31.7)þ 130 (21.0) 135 (27.8) 127 (27.3) 138 (33.8)
GFR (ml/min) 62 (14.4) 58 (13.0)þ 67 (20.3) 64 (18.3) 63 (14.1) 58 (12.8)
MAP (mmHg) 100 (11.2) 97 (12.9) 105 (10.2) 98 (10.1) 100 (12.1) 97 (13.8)
Change in GFR (ml/min) 3.9 (6.1) 2.6 (5.7) 4.8 (6.3)
Change in MAP (mmHg) 3.6 (12.7) 7.2 (10.6) 2.9 (13.5)
Symptoms of SW, n (%) 12 of 32 (38) 5 of 10 (50) 7 of 22 (32)
All results are means; SDs are given in parentheses.
BFC¼ basal fasting cortisol; CST¼ stimulated cortisol; SCr¼ serum creatinine; GFR¼ glomerular ﬁltration rate; MAP¼mean arterial
pressure; SW¼ steroid withdrawal.
*P¼ 0.028 vs mean time on steroids in group D; þP<0.01 vs mean baseline in all patients; yP<0.0001 vs group D after SW; zP¼ 0.002 vs
group D at baseline.
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with the adrenal response upon the low-dose ACTH
stimulation test (Table 5). The occurrence of symptoms
and arterial hypotension may be the more sensitive
‘markers’ for the susceptibility to worsening of renal
graft function from SW than the adrenocortical
response assessed by ACTH stimulation test.
Nevertheless, no deﬁnite conclusion can be drawn
regarding the cause and effect relationship between SW
and changes in renal graft function due to intraglo-
merular pressure mechanisms.
A more clear-cut picture can be drawn from the
present results with respect to the interdependence
of symptoms related to the cessation of steroid medica-
tion and adrenocortical response in renal transplant
patients. About a third of all patients in this study
developed manifestations related to SW, such as
fatigue, arthralgias, muscular weakness, loss of appe-
tite, hypotension or headaches (Table 2). This percent-
age was even higher in patients with an inadequate
LDS test (Table 5), and rose to 100% in those with
low BFC concentration prior to cessation of steroid
medication. The latter is in accordance with ﬁndings
in non-transplant patients undergoing long-term corti-
costeroid therapy [14]. Moreover, a similar pattern
was revealed for changes in MAP. As expected,
MAP dropped by 6mmHg when all patients were
analysed together. In fact, arterial hypertension, or
poorly controlled arterial blood pressure, are among
the most relevant complications of chronic steroid
therapy. Therefore, lowering of MAP is a beneﬁ-
cial effect of SW. However, the decrease in blood
pressure was more pronounced in patients with
low BFC (Table 2) and/or inadequate CST concen-
tration after ACTH administration (CST <550 nmol/l;
Table 5). As the occurrence of symptoms from SW
matches well with these groups of patients, it is
conceivable that at least part of the manifesta-
tions, such as fatigue and headache, are conferred by
changes in blood pressure. Finally, our study has
revealed time on steroid medication to be the most
relevant determinant for the occurrence of symptoms
from cessation of steroids in renal transplant patients.
A note of caution may be warranted with regard to
the steroid tapering scheme used in our trial. Except
for study conditions with frequent and careful
monitoring of the patients undergoing SW, a more
prolonged course of stepwise dose reduction may be
advisable.
What are the practical implications from our ﬁnd-
ings? Our data indicate that renal transplant patients on
long-term corticosteroid therapy are comparable in
general regarding adrenocortical function with patients
receiving steroids for other indications. Thus, similar
complications can be anticipated when therapy is
stopped, and the same precautions should be taken,
especially in patients after many years on treatment.
Surprisingly, cessation of steroid medication almost
exclusively failed because of symptomatic manifesta-
tions, and not due to graft failure. However, reinstitu-
tion and continuation of steroids was necessary only
in six patients (Table 3). As SW seems clearly less likely
to result in complications when performed within the
ﬁrst 2 years of therapy, it is recommended to stop
medication within this period. Measuring BFC prior
to cessation of therapy is helpful, as low levels can
identify patients susceptible to develop symptoms after
SW. With regard to the renal graft, it should be kept
in mind that worsening kidney function after cessation
of steroids may not always indicate rejection, but is
probably more likely to be due to systemic and renal
haemodynamic effects of corticosteroid hormones.
Thus, prior to resumption of long-term steroid therapy,
this possibility should be considered, and a graft biopsy
performed to avoid unnecessary treatment.
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